AqVida - API Sourcing and Supply Chain Management, Generic Developments Licensing

AqVida offers a range of services for the pharmaceutical industry. Our main focus lies in the fields of:

• API sourcing and supply chain management
• Development of generic products (e.g. biogenerics and oncology products)
• Licensing of pharmaceutical products

Our spectrum of services however does not stop at the provision and development of innovative drugs, we also provide everything necessary to successfully launch new products within a short period of time and with efficient allocation of resources. This implies familiarity with the markets and knowledge about the industry, and we offer finished dosages and raw materials of high quality from our co-operation partners. We also provide the necessary documentation and technical understanding to fulfil the requirements to register the products in your country.

API sourcing and supply chain management

AqVida offers sourcing of high quality API and is well positioned with its office in Hangzhou, China, which enables direct and fast contact to numerous local manufacturers. Our relationships with cooperation partners around the world enable us to offer high quality APIs like e.g. Paclitaxel, Gemcitabine or Docetaxel, which we are supplying to leading companies in Europe and Latin America.

Our quality assurance systems and regular audits carried out at our manufacturing sites ensure a high quality and security of the products provided. We also arrange for audits from European authorities for our main suppliers.

Developments of biosimilars and genetics

AqVida has its own product developments, such as, G-CSF (Filgrastim) and Oxaliplatin. Other products currently under development are Interferon ß 1a and Imatinib.

AqVida is focussing on the development of innovative products, particularly biosimilars and high barrier to entry generics. Expert scientists compile dossiers in CTD format and DMFs for regulated and less regulated markets. Our regulatory affairs team is familiar with European DCPs and national registration procedures in several countries.

Granulocyte colony-stimulating factor

Our biogeneric G-CSF has been registered in various countries, e.g. in Russia under the name Leucita. It is a granulocyte colony-stimulating factor (G-CSF) used to stimulate the proliferation and differentiation of granulocytes, which is produced by recombinant DNA technology. Furthermore we have initiated the development of Interferon β 1a, where we have a very strong market advantage due to the very cost competitive production process.

Oncology products

In the field of oncology products we have Oxaliplatin and Vinorelbine in registration processes in several European countries. Imatinib is currently under development and will be available for licensing within 2009.

Licensing and distribution of pharmaceutical products

A further column of AqVida’s services and strategy is the licensing and distribution of pharmaceutical products. The firm’s own presences in Mexico and Russia allow better penetration of these markets and reduces time to market significantly. We have registrations of several products, e.g. a test for peripheral autonomic neuropathy and early detection test for diabetic foot syndrome (neuropad), an Insulin delivery device and various oncology products.

In Europe we can provide extended market insight, experience and knowledge about national and DCP registration procedures and conclude and arrange audits. It puts us in the position to offer high quality services ensuring an added value to your company.